



## Supplementary Figure 1




**Supplementary Figure 1** | Schematic representation of the utilized brain slice for TTC staining and immunohistochemistry, which was located at -1.06 mm and -2.18 mm in adult mice (Modified from the atlas of Franklin and Paxinos<sup>38</sup>. Confirming H/I model by TTC staining, the brain tissues from the boxed ipsilateral penumbra (③) and contralateral area (④) were used for RT-PCR and Western blot analyses.

## Supplementary Figure 2



**Supplementary Figure 2 | Expression levels of glial or neuronal markers in brain tissues from the H/I mice and primary culture cells.** (a) Western blot analysis was performed on brain tissues from the H/I mice using the indicated antibodies. (b) Immunohistochemistry was performed with Anti-TIM-3 (red) and Iba-1 antibodies (green) on coronal sections of the H/I mice. Scale bar: 20  $\mu$ m. (c-d) Brain cells isolated from ischemic ipsilateral and contralateral hemispheres were stained with antibodies against Iba-1, GFAP, or secondary antibody (Molecular probe, #A21441), and analyzed by flow cytometry. The data shown are representative of at least three independent experiments. (e) RT-PCR analysis was performed in primary cultured glial cells and neuronal cells using the indicated primers. GFAP forward: 5`-AAG CTC CAA GAT GAA ACC AAC CTG A-3`, reverse: 5`-CCA CGA TGT TCC TCT TGA GGT GG-3`; and TREM2 forward: 5`-ATG GGA CCT CTC CAC CAG TT, reverse: 5`-TCA CGT ACC TCC GGG TCC A; and Iba-1 forward: 5`-GGA TTT GCA GGG AGG AAA AG-3`, reverse: 5`-TGG GAT CAT CGA GGA ATT G-3`; and MAP2 forward: 5`-TTG GCT CAC TTG ACA ATG CTC ACC-3`, reverse: 5`-AAT ATG ACA CCT GCT CAG AGC CCA-3`; and NeuN forward: 5`-CCA GGC ACT GAG GCC AGC ACACAG C-3`, reverse: 5`-CTC CGT GGG GTC GGA AGG GTG G-3`.


### Supplementary Figure 3




**Supplementary Figure 3 | TIM-3 expression is closely linked with HIF-1 $\alpha$**  Three putative HRE sites within p(1517)luc were targeted for mutagenesis. The mutations of 2 base pairs in each of the HREs were made using a site-directed mutagenesis kit, and confirmed using DNA sequencing. The regions of mutated HREs are indicated at the bottom. Mouse primary mixed glial cells were transfected with the TIM-3 luciferase reporter constructs or PGL3-basic control reporter, and incubated under hypoxic or normoxic conditions for 24 h. Relative promoter activity is expressed as the ratio of luciferase activity/ $\beta$ -galactosidase activity.

# Supplementary Figure 4


a



Day 1




## Supplementary Figure 4 (continued)



**Supplementary Figure 4 | A TIM-3 blocking antibody significantly reduces brain injury and edema formation after hypoxia-ischemia (a)** Representative images of Coronal MRI (T2 weighted image) brain slices after 24 h from H/I mice treated with 100  $\mu\text{g}$  of IgG ( $n=4$ ) or anti-TIM-3 ( $n=4$ ). **(b)** Representative images of Coronal MRI (T2 weighted image) brain slices after indicated time from H/I mice treated with 100  $\mu\text{g}$  of IgG ( $n=4$ ) or anti-TIM-3 ( $n=4$ ). **(c)** Representative images of ADC maps brain slices after 24 h from H/I mice treated with 100  $\mu\text{g}$  of IgG ( $n=4$ ) or anti-TIM-3 ( $n=4$ ). Edema volume was quantified with Image J analyzer and were calculated with [(ipsilateral volume-contralateral volume)/contralateral volume]  $\times 100$  and expressed as a percentage of the damaged ipsilateral hemisphere.

## Supplementary Figure 5




**Supplementary Figure 5 | Neutrophil migration is increased in the ipsilateral cortex of H/I mice.** (a) Antibodies against MPO and Gr-1 were used to perform immunohistochemistry on coronal sections of the H/I mice 24 h after injury. Scale bar: 20 μm. The graph shows the mean number of MPO<sup>+</sup>Gr-1<sup>+</sup> cells per mm<sup>2</sup> (mean ± s.d. from three independent experiments). (b) RT-PCR analysis and (c) Western blot analysis were performed on brain tissues from H/I mice with MPO-specific primers and antibody, respectively. Relative levels of MPO transcripts and proteins are shown as graphs. The data shown are representative of at least three independent experiments (b,  $p=0.0003$  compared with the contralateral control; c,  $p=0.009$  compared with the contralateral control).




# Supplementary Figure 6

**a**




**b**






## Supplementary Figure 6 (continued)



**Supplementary Figure 6 | The migration of neutrophils is increased in the presence of glial cells under hypoxic conditions.** (a) Splenocytes were isolated from C57BL/6 mice, and incubated in a transwell system with primary glial cells or MEF cells (C57BL/6) under hypoxic or normoxic conditions for 24 h. The cells were analyzed by flow cytometry using antibodies against CD11b and Gr-1. The percentage of Gr-1<sup>high</sup>CD11b<sup>high</sup> cells is expressed as the mean  $\pm$  s.d. from three independent experiments. (b) Splenocytes ( $5 \times 10^5$ ) were isolated from C57BL/6 mice, and incubated in a transwell system with or without  $2 \times 10^5$  primary cultured glial cells under hypoxic or normoxic conditions for 24 h. The percentage of Gr-1<sup>high</sup>CD11b<sup>high</sup> cells is expressed as the mean  $\pm$  s.d. from three independent experiments. (c) Schematic illustration of our transwell system-based neutrophil transmigration assay.


## Supplementary Figure 7




**Supplementary Figure 7 | The migration of neutrophils into ischemic ipsilateral regions is decreased in TIM-3-blocking antibody-treated H/I mice.** Representative confocal microscopic images of coronal sections from control IgG- or TIM-3 blocking antibody-treated H/I mice. Scale bar: 50  $\mu$ m.

# Supplementary Figure 8

a




b




## Supplementary Figure 8 (continued)

**C**




## Supplementary Figure 8 (continued)



**Supplementary Figure 8 | The TIM-3-blocking antibody reduces neutrophil migration after hypoxia-ischemia.** (a) Schematic representation of the utilized brain slice for immunohistochemistry, which was located at bregma 2 to -2 mm in adult mice (Modified from the atlas of Franklin and Paxinos<sup>38</sup>). (b-d) Immunohistochemistry was performed on coronal sections from control IgG- or TIM-3-blocking-antibody-treated H/I mice at the indicated times after injury using antibodies against MPO and Gr-1. Scale bar: 20  $\mu$ m.


## Supplementary Figure 9




**Supplementary Figure 9** | Similar events are observed in the primary glial cells and cortex tissues from *LysM-Hif-1α<sup>-/-</sup>* mice. **(a)** Real time quantitative RT-PCR analysis was performed in primary microglia cultured from *HIF-1α<sup>+/+/+</sup>* or *LysM-Hif-1α<sup>-/-</sup>* mice ( $n=6$ ) using HIF-1α primer. **(b)** The transcript levels of IL-1β and CXCL1 were examined in brain tissues from the contralateral cortex and ischemic ipsilateral cortex of *HIF-1α<sup>+/+/+</sup>* or *LysM-Hif-1α<sup>-/-</sup>* mouse 24 h after hypoxia and ischemic injury ( $n=3$ ). Data shown are presented as the mean  $\pm$  s.d.

# Supplementary Figure 10

**a**



**b**



**c**

Mice	Lentivirus	Number with the indicated score					n	Mean Score (± s.d.)
		0	1	2	3	4		
<i>LysM-Hlf-1α<sup>-/-</sup></i>	LV-GFP	1	3	2	0	0	6	1.1±0.7
	LV-TIM3-GFP	0	1	2	3	0	6	2.3±0.8*

**Supplementary Figure 10** | (a) LV-TIM3-GFP or LV-GFP was injected using an stereotaxic instrument. Five days after intracranial injection of lentiviral vectors, glial cells from the injected region were subjected to FACS analysis using antibody against TIM-3 (eBioscience, RMT-3-23). The graph shows the results from three mice. (b) Schematic drawing of the injection sites. (c) Neurological scoring was determined after 24 h of H/I in mice LV-GFP ( $n=6$ ) or LV-TIM3-GFP ( $n=6$ ).



# Supplementary Figure 11

## a Blots and Gels; Figure 1

Fig.1a







Fig.1b





## b Blots and Gels; Figure 2

Fig.2c




Primary glial cell

Fig.2d






Neuron

Fig.2e







# Supplementary Figure 11 (continued)



**Fig.2g**



**Fig.2h**





## c Blots and Gels; Figure 3f





## Supplementary Figure 11 (continued)

### d Blots and Gels; Figure 4




### e Blots and Gels; Figure 5




## Supplementary Figure 11 (continued)

### f Blots and Gels; Figure 6c




### 9 Blots and Gels; Figure 7

#### Fig.7a



#### Fig.7b



Supplementary Figure 11 | Full scans of blots and gels for Figure 1 (a), Figure 2 (b), Figure 3 (c), Figure 4 (d), Figure 5(e), Figure 6 (f), and Figure 7 (g).